Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 3/20 | 0.50 |
| ▸ | KIF11 | P52732 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13291465 | 0.91 | CXCR3 (0.48) | CXCR3MEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12463878 | 0.86 | CXCR3 (0.57) | CXCR3KIF11MEN1CYP1A2CYP3A4 | |
| SCHEMBL12463993 | 0.77 | CXCR3 (0.65) | CXCR3MEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12463674 | 0.76 | POLB (0.48) | CXCR3MEN1KMT2APOLBPDE10A | |
| SCHEMBL12463668 | 0.74 | CXCR3 (0.56) | CXCR3KIF11MEN1CYP1A2CYP3A4 | |
| SCHEMBL12829873 | 0.73 | CXCR3 (0.51) | CXCR3KIF11MEN1KMT2APDE10A | |
| SCHEMBL12536747 | 0.73 | CXCR3 (0.57) | CXCR3MEN1KMT2APDE10ALMNA | |
| SCHEMBL449210 | 0.73 | CXCR3 (0.59) | CXCR3MEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL12463678 | 0.72 | KIF11 (0.49) | CXCR3KIF11 | |
| SCHEMBL12464101 | 0.72 | CXCR3 (0.48) | CXCR3KIF11POLBUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170246168-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170246168-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2017-08-31 | — | — | US | disclosed |
| US-9649312-B2 | Compositions and methods of treatment of cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2017-05-16 | — | — | US | disclosed |
| US-9649312-B2 | Compositions and methods of treatment of cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160324858-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2016-11-10 | — | — | US | disclosed |
| US-20160324858-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2016-11-10 | — | — | US | disclosed |
| US-20130190495-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190495-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2013-07-25 | — | — | US | disclosed |
| US-8349853-B2 | Detection defect in gene expression of hedgehog gene; diagnosis of cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349853-B2 | Detection defect in gene expression of hedgehog gene; diagnosis of cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2340838-A1 | Compositions and Methods of Treatment of Cancer | Minerva Biotechnologies Corporation (US) | 2011-07-06 | — | — | EP | disclosed |
| EP-2329822-A1 | Compositions and methods of treatment of cancer | Minerva Biotechnologies Corporation (US) | 2011-06-08 | — | — | EP | disclosed |
| EP-1425016-B1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2010-06-02 | — | — | EP | disclosed |
| EP-2116248-A1 | Compositions and Methods of Treatment of Cancer | Minerva Biotechnologies Corporation (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20080064680-A1 | Methods for Diagnosis and Treatment of Cancer | MINERVA BIOTECHNOLOGIES CORPORATION | 2008-03-13 | — | — | US | disclosed |
| US-20080064680-A1 | Methods for Diagnosis and Treatment of Cancer | MINERVA BIOTECHNOLOGIES CORPORATION | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324858-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MUC1, TP53, BRCA1 | CXCR3 109/4885KIF11 2340/4885MEN1 738/4885 |
| US-20080064680-A1 | Methods for Diagnosis and Treatment of Cancer | MUC1, CD44, TP53 | CXCR3 1257/4885KIF11 1156/4885MEN1 1582/4885 |
| US-20130190495-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MUC1, TP53, BRCA1 | CXCR3 109/4885KIF11 2340/4885MEN1 738/4885 |
| US-20170246168-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MUC1, TP53, BRCA1 | CXCR3 109/4885KIF11 2340/4885MEN1 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.